Sanofi says COVID-19 vaccine candidate yields positive trial data – Reuters

A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. REUTERS/Benoit Tessier

Register now for FREE unlimited access to Reuters.com

PARIS, June 24 (Reuters) – Sanofi’s COVID-19 vaccine candidate, which is modelled on the virus’s Beta antigen, delivered 72% efficacy in adults against the Omicron strain, the French drugmaker said on Friday, citing data gathered in a study.

“Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation,” the firm, which is developing the vaccine jointly with Britain’s GSK(GSK.L), said in a statement.

The new data supporting its booster vaccine will be submitted to regulatory authorities, Sanofi added, reiterating its plan to start marketing its jab later this year.

Register now for FREE unlimited access to Reuters.com

Reporting by Tassilo Hummel; Editing by Clarence Fernandez

Our Standards: The Thomson Reuters Trust Principles.

Source